Home The Word Brain	My Amedeo FAQ Privacy About
	Explore this week’s CC Journal Club 90‑sec video • 4‑min audio • paper abstracts

Chronic Renal Failure

Free Subscription Articles published in Kidney Int Retrieve available abstracts of 52 articles: HTML format

Single Articles

April 2025
1. ERICKSON KF, Fotheringham J
   Is online hemodiafiltration a cost-effective alternative to conventional hemodialysis?
   Kidney Int. 2025;107:602-605.
   PubMed     Abstract available
   
   
   March 2025
2. STACK AG
   Can we crystallize the role of urate-lowering treatment in chronic kidney disease?
   Kidney Int. 2025;107:394-396.
   PubMed     Abstract available
   
   
   
3. JENSEN M, Jensen BL
   Soluble guanylate cyclase as a direct target for pharmacologic mitigation of chronic kidney disease.
   Kidney Int. 2025;107:391-394.
   PubMed     Abstract available
   
   
   February 2025
4. BONNIN-MARQUEZ A, Jankowski J, Maas SL, Hermann J, et al
   Guanidinylation compromises the anti-inflammatory and anti-oxidative properties of apolipoprotein A-I in chronic kidney disease progression.
   Kidney Int. 2025 Feb 24:S0085-2538(25)00171-1. doi: 10.1016/j.kint.2025.
   PubMed     Abstract available
   
   
   
5. ZHU D, Judge PK, Wanner C, Haynes R, et al
   THE PREVENTION AND MANAGEMENT OF CHRONIC KIDNEY DISEASE AMONG PATIENTS WITH METABOLIC SYNDROME.
   Kidney Int. 2025 Feb 20:S0085-2538(25)00141-3. doi: 10.1016/j.kint.2024.
   PubMed     Abstract available
   
   
   
6. FUCHS MAA, Burke EJ, Latic N, Murray S, et al
   Fibroblast growth factor 23 and fibroblast growth factor receptor 4 promote cardiac metabolic remodeling in chronic kidney disease.
   Kidney Int. 2025 Feb 7:S0085-2538(25)00087-0. doi: 10.1016/j.kint.2025.
   PubMed     Abstract available
   
   
   
7. HSU SN, Stephen LA, Phadwal K, Dillon S, et al
   Mitochondrial dysfunction and mitophagy blockade contribute to renal osteodystrophy in chronic kidney disease-mineral bone disorder.
   Kidney Int. 2025 Feb 6:S0085-2538(25)00085-7. doi: 10.1016/j.kint.2025.
   PubMed     Abstract available
   
   
   
8. HUGHES A, Scholes-Robertson N, Coghlan D, Wu R, et al
   Identifying strategies for disseminating research to patients with chronic kidney disease and caregivers: a workshop report.
   Kidney Int. 2025 Feb 6:S0085-2538(25)00083-3. doi: 10.1016/j.kint.2025.
   PubMed     Abstract available
   
   
   January 2025
9. SCHOUTEN AEM, Fischer F, Blankestijn PJ, Vernooij RWM, et al
   A health economic evaluation of the multinational, randomized controlled CONVINCE trial - cost-utility of high-dose online hemodiafiltration compared to high-flux hemodialysis.
   Kidney Int. 2025 Jan 21:S0085-2538(25)00068-7. doi: 10.1016/j.kint.2024.
   PubMed     Abstract available
   
   
   
10. KETTELER M, Evenepoel P, Holden RM, Isakova T, et al
    Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
    Kidney Int. 2025 Jan 10:S0085-2538(24)00810-X. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
11. HOLE B, Coast J, Caskey FJ, Selman LE, et al
    A choice experiment of older patients' preferences for kidney failure treatments.
    Kidney Int. 2025;107:130-142.
    PubMed     Abstract available
    
    
    
12. WATANABE S, Sawa N, Hiramatsu R, Oba Y, et al
    The Case | A patient with chronic kidney disease and new-onset heart failure.
    Kidney Int. 2025;107:195-196.
    PubMed    
    
    
    December 2024
13. MIMURA I, Chen Z, Natarajan R
    Epigenetic alterations and memory: key players in the development/progression of chronic kidney disease promoted by acute kidney injury and diabetes.
    Kidney Int. 2024 Dec 24:S0085-2538(24)00918-9. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
14. HANOUNEH M, Stewart S, Aktay R, Fang AS, et al
    Chylothorax and chylopericardium in a dialysis patient.
    Kidney Int. 2024;106:1190.
    PubMed    
    
    
    
15. BOBOT M, Burtey S
    New insights into mechanisms underlying cognitive impairment in chronic kidney disease.
    Kidney Int. 2024;106:1020-1022.
    PubMed     Abstract available
    
    
    November 2024
16. AMINI M, Frisch J, Jost P, Sarakpi T, et al
    Purinergic receptor P2X7 regulates interleukin-1alpha mediated inflammation in chronic kidney disease in a reactive oxygen species-dependent manner.
    Kidney Int. 2024 Nov 19:S0085-2538(24)00798-1. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
17. VAN DEN BERG CW, Dumas SJ, Little MH, Rabelink TJ, et al
    Challenges in maturation and integration of kidney organoids for stem cell-based renal replacement therapy.
    Kidney Int. 2024 Nov 19:S0085-2538(24)00806-8. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
18. KO TY, Wu CC, Hsieh MY, Yang CW, et al
    A randomized controlled trial evaluated the efficacy and safety of apixaban for prevention of recurrent thrombosis after thrombectomy of hemodialysis vascular access.
    Kidney Int. 2024 Nov 15:S0085-2538(24)00792-0. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
19. GHANG B, Park J, Lee JS, Lim JS, et al
    Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy.
    Kidney Int. 2024 Nov 15:S0085-2538(24)00789-0. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
20. GEORGERY H, Lengele JP, Leflot S, Gillion V, et al
    Recurrent iodine-induced sialadenitis in a patient undergoing hemodialysis: is this really ineluctable?
    Kidney Int. 2024;106:997.
    PubMed    
    
    
    
21. HAMDAN H, Roshanravan B
    Dialysis modality and quality of life: more answers yet more questions.
    Kidney Int. 2024;106:792-794.
    PubMed     Abstract available
    
    
    
22. SHAREEF Z, Spradling M, Blair P, Quinones-Vargas I, et al
    Appendicitis associated with sevelamer use in a patient receiving peritoneal dialysis.
    Kidney Int. 2024;106:1000.
    PubMed    
    
    
    
23. YANAGI T, Kikuchi H, Takeuchi K, Susa K, et al
    ULK1-regulated AMP sensing by AMPK and its application for the treatment of chronic kidney disease.
    Kidney Int. 2024;106:887-906.
    PubMed     Abstract available
    
    
    October 2024
24. IKIZLER TA, Drueke TB, Floege J, Wong G, et al
    Avoiding Arrythmias by Personalizing Dialysate Concentration: A Case for Precision Medicine in Dialysis Patients.
    Kidney Int. 2024 Oct 22:S0085-2538(24)00721-X. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
25. CHARYTAN DM, Winkelmayer WC, Granger CB, Middleton JP, et al
    Effects of dialysate potassium concentration of 3.0mEq/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0mEq/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia.
    Kidney Int. 2024 Oct 22:S0085-2538(24)00722-1. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
26. BAJAJ A, Arora M, Bhatt U
    The Case | Dark dialysate after colonoscopy.
    Kidney Int. 2024;106:761-762.
    PubMed    
    
    
    
27. SHARMA Y, Tiwari V, Tyagi V, Bhargava V, et al
    CAPD catheter obstruction by fallopian tubes.
    Kidney Int. 2024;106:760.
    PubMed    
    
    
    
28. CHEN WLJ, Fung KFK, Chan EY
    Nephronophthisis-associated ciliopathy with brachydactyly, medullary cysts, and chronic kidney disease.
    Kidney Int. 2024;106:759.
    PubMed    
    
    
    September 2024
29. BISHOP NC
    Unpicking the multi-omic response to endurance training: relevance for exercise benefits in chronic kidney disease.
    Kidney Int. 2024 Sep 18:S0085-2538(24)00646-X. doi: 10.1016/j.kint.2024.
    PubMed    
    
    
    
30. TONG KC, Wee KW
    Cardiovascular disease as a risk factor for frailty in dialysis patients.
    Kidney Int. 2024;106:537-538.
    PubMed    
    
    
    
31. GARG AX, Young A
    Improving the management of chronic kidney disease in primary care by enhancing laboratory reports with additional information and follow-up procedures.
    Kidney Int. 2024;106:366-368.
    PubMed     Abstract available
    
    
    August 2024
32. BERGERON NAD, Candellier A, Rousseau-Gagnon M, Mac-Way F, et al
    Unusual cause of retroperitoneal leak in a patient undergoing peritoneal dialysis.
    Kidney Int. 2024;106:321.
    PubMed    
    
    
    
33. TOUSSAINT ND, Badve SV
    Normalizing serum phosphate based on association, not causation? Lessons in dialysis should have taught us not to fix what we can't prove is broken.
    Kidney Int. 2024;106:195-199.
    PubMed    
    
    
    
34. HAMANO T, Fukagawa M
    Results of the EPISODE trial plead for reasonable practice-based serum phosphate lowering in patients on dialysis.
    Kidney Int. 2024;106:191-195.
    PubMed    
    
    
    July 2024
35. ROSE M, Fischer FH, Liegl G, Strippoli GF, et al
    The CONVINCE randomized trial found positive effects on quality of life for patients with chronic kidney disease treated with hemodiafiltration.
    Kidney Int. 2024 Jul 30:S0085-2538(24)00534-9. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
36. ZIMMERMANN S, Mathew A, Bondareva O, Elwakiel A, et al
    Chronic kidney disease leads to microglial potassium efflux and inflammasome activation in the brain.
    Kidney Int. 2024 Jul 30:S0085-2538(24)00535-0. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
37. JOHNSON RJ, Mandell BF, Schlessinger N, Mount DB, et al
    Controversies and practical management of patients with gout and chronic kidney disease.
    Kidney Int. 2024 Jul 19:S0085-2538(24)00473-3. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
38. STAMELLOU E, Noels H, Floege J
    Factor XI inhibition in hemodialysis patients: the safer anticoagulation?
    Kidney Int. 2024;106:21-23.
    PubMed     Abstract available
    
    
    
39. SAHINOZ M, Ikizler TA
    Inflammasome activation: unraveling the link between chronic kidney disease and atrial fibrillation.
    Kidney Int. 2024;106:6-9.
    PubMed    
    
    
    
40. MEDINA RANGEL PX, Ishibe S
    Preventing MMP23-mediated cleavage of podocyte RARRES1: a novel strategy to halt chronic kidney disease progression?
    Kidney Int. 2024;106:16-18.
    PubMed     Abstract available
    
    
    
41. WONG G, Guha C, Mallitt KA, van Zwieten A, et al
    The randomized controlled trial (NAVKIDS2) of a patient navigator program created for children with chronic kidney disease.
    Kidney Int. 2024 Jul 1:S0085-2538(24)00450-2. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    May 2024
42. CORKEN AL, Ong V, Kore R, Ghanta SN, et al
    Platelets, Inflammation, and Purinergic Receptors in Chronic Kidney Disease.
    Kidney Int. 2024 May 29:S0085-2538(24)00381-8. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
43. CHAN GC, Kalantar-Zadeh K, Ng JK, Tian N, et al
    Frailty in Patients on Dialysis.
    Kidney Int. 2024 May 3:S0085-2538(24)00315-6. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
44. GOLDSTEIN CE, Taljaard M, Nicholls SG, Beaucage M, et al
    The Ottawa Statement implementation guidance document for cluster randomized trials in the hemodialysis setting.
    Kidney Int. 2024;105:898-911.
    PubMed     Abstract available
    
    
    
45. CULLIS B, McCulloch M, Finkelstein FO
    Development of PD in lower-income countries: a rational solution for the management of AKI and ESKD.
    Kidney Int. 2024;105:953-959.
    PubMed     Abstract available
    
    
    April 2024
46. WONG G, Bernier-Jean A, Rovin B, Ronco P, et al
    Time for Action: Recognising chronic kidney disease as a major non-communicable disease driver of premature mortality.
    Kidney Int. 2024 Apr 2:S0085-2538(24)00247-3. doi: 10.1016/j.kint.2024.
    PubMed    
    
    
    
47. 
    KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
    Kidney Int. 2024;105.
    PubMed    
    
    
    
48. LEVIN A, Ahmed SB, Carrero JJ, Foster B, et al
    Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns.
    Kidney Int. 2024;105:684-701.
    PubMed     Abstract available
    
    
    March 2024
49. WINKELMAYER WC, Lensing AWA, Thadhani RI, Mahaffey KW, et al
    A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis.
    Kidney Int. 2024 Mar 25:S0085-2538(24)00196-0. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
50. PIETERS TT, Besseling PJ, Bovee DM, Rookmaaker MB, et al
    Discrepancies between transcutaneous and estimated glomerular filtration rates in rats with chronic kidney disease.
    Kidney Int. 2024 Mar 19:S0085-2538(24)00187-X. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
51. GILL JS, Chadban SJ
    Pretransplant screening for coronary artery disease: data are required before practice change.
    Kidney Int. 2024;105:470-472.
    PubMed     Abstract available
    
    
    February 2024
52. LEE J, Lee J, Kim K, Lee J, et al
    Antibiotic-induced intestinal microbiota depletion can attenuate the acute kidney injury to chronic kidney disease transition via NADPH oxidase 2 and trimethylamine-N-oxide inhibition.
    Kidney Int. 2024 Feb 29:S0085-2538(24)00163-7. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Chronic Renal Failure is free of charge.